Clinical trials: Biotherapy
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Trial name
- NCT07383441
- Testing
- Axitinib, Biospecimen Collection, Bone Scan
- Where
- 41 sites in United States
- Volunteers
- 718 people
- Sponsor
- SWOG Cancer Research Network
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biological Therapy
A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments.
- Conditions
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biological Therapy, Biomarkers
- Trial name
- NCT06801353
- Testing
- Stapokibart, Mometasone Furoate Nasal Spray (MFNS)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Beijing Tongren Hospital
Rheumatoid Arthritis
The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients
SYBRA is an open-label, phase 3, randomized controlled clinical trial that aims to assess the use of synovial biopsies in predicting response to biologic therapy in patients with rheumatoid arthritis that have failed…
- Trial name
- SYBRA (NCT05379322)
- Testing
- Anti-TNF, JAK inhibitor
- Where
- United Arab Emirates
- Sponsor
- Abu Dhabi Stem Cells Center
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's white blood cells in the laboratory and reinfusing them may cause a stronger immune response…
- Trial name
- NCT00045357
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Fred Hutchinson Cancer Center
Ulcerative Colitis (UC)
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL）
This is a national prospective, multicenter, observational study. A total of 200 eligible patients will be enrolled from 10 hospitals across the country.
- Trial name
- PRECAL (NCT07721441)
- Testing
- fecal calprotectin test
- Where
- 10 sites in China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Leukemia
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing.
- Trial name
- NCT00003405
- Testing
- recombinant interferon alfa, amifostine trihydrate, bromodeoxyuridine
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation.
- Trial name
- NCT00003153
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia, Lymphoma
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00012207
- Testing
- aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Allergic Rhinitis
A Novel Biologic Therapy for Perennial Allergic Rhinitis
This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as a sub-cutaneously administered…
- Trial name
- NCT03360071
- Testing
- Allergen Immunotherapy Extract, Allergen Immunotherapy Control
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Rotator Cuff Tendinopathy
Effect of Plasma Rich in Growth Factors in Rotator Cuff Tendinopathy
The overall objective of the study is to assess the effectiveness of the treatment of degenerative rotator cuff tendinopathy using the application of plasma rich in growth factors (PRGF).
- Trial name
- NCT01915979
- Testing
- Plasma rich in growth factors (PRGF), Celestone cronodose (Bethametasone)
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias
Asthma
Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy
Neutrophils and eosinophils can have different functions. Depending on their environment, they can be more or less active, with more or less inflammatory activity.
- Trial name
- CaPHe (NCT05972213)
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Inflammatory Bowel Disease
Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease
This is a monocentric prospective study for the collection of biological samples (blood and biopsies) to be used for in vitro biomarker assay(s) performed to identify predictive markers of response to biological treatments in…
- Trial name
- IBDOT (NCT02693340)
- Testing
- sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
REstore Working Ability in RheumatoiD Arthritis
The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo.
- Trial name
- REWARD (NCT01405326)
- Testing
- adalimumab
- Where
- 4 sites in Finland
- Volunteers
- 160 people
- Sponsor
- The Rheumatological Center of Helsinki
Melanoma (Skin)
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006237
- Testing
- interleukin-2, filgrastim, interferon alfa
- Where
- 297 sites in United States, Australia
- Volunteers
- 432 people
- Sponsor
- SWOG Cancer Research Network
Anterior Cruciate Ligament Injuries
Biologic Therapy to Prevent Osteoarthritis After ACL Injury
Anterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury.
- Trial name
- NCT03968913
- Testing
- Anakinra injection, sterile saline injection
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Psoriatic Arthritis (PsA)
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE2 (NCT03671148)
- Testing
- Risankizumab
- Where
- 138 sites in United States, Argentina and 23 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
Asthma
Creation of Home-based Asthma Real-World Measures With Mobile Health Study
Four novel biologic therapies (benralizumab, dupilumab, mepolizumab, reslizumab) have been recently approved for moderate-to-severe, eosinophilic or oral steroid-dependent asthma.
- Trial name
- CHARM (NCT04462224)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Jewish Health
Psoriasis, Psoriatic Arthritis (PsA)
Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors
This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10…
- Conditions
- Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors, Metabolic Syndrome (MetS)
- Trial name
- GENBIOPSO (NCT07041112)
- Testing
- Biologic therapy for psoriasis
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Juan Ruano Ruiz
Ulcerative Colitis
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC.
- Trial name
- NCT06109441
- Testing
- ALTB-268
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- AltruBio Inc.